Understanding FDA Peptide Categories: What Category 1, 2, and 3 Mean for Research
Key Takeaways
- The FDA uses a 3-tier category system to classify bulk drug substances for compounding
- Category 1 allows compounding — but it is not the same as FDA approval
- Category 2 substances are restricted due to safety concerns
- Research-grade peptides operate under a different regulatory framework than clinical compounding
With the current regulatory changes around peptide access making headlines, there has been considerable confusion about what the FDA’s category system actually means. This guide breaks down the framework so researchers and industry participants can understand exactly where things stand.
The Section 503A Framework
Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. Under this section, pharmacies can prepare customized medications using bulk drug substances — but only if those substances meet specific regulatory criteria.
The FDA evaluates nominated bulk drug substances and places them into one of three categories. While described as interim administrative groupings, they carry significant practical impact.
The Three Categories
Category 1
Under Evaluation — May Be Compounded
Sufficient supporting safety information for continued evaluation. Licensed 503A pharmacies may compound these under valid physician prescriptions. This is the category most peptides occupied before 2023.
Category 2
Safety Concerns — Cannot Be Compounded
Identified as presenting significant safety risks. Cannot be used in compounding unless FDA authorizes through formal rulemaking. In September 2023, 19 peptides were moved here.
Category 3
Insufficient Data — Cannot Be Compounded
Lacks sufficient documentation or evidence for FDA evaluation. Cannot be compounded as active ingredients under any circumstances.
Critical Distinctions
Category 1 ≠ FDA Approved
This is the most commonly misunderstood point. Category 1 means a substance can be compounded while under evaluation. FDA approval requires a completely different process:
- Formal clinical trials (Phase I, II, and III)
- Safety and efficacy review
- Labeling approval and manufacturing validation
- New Drug Application (NDA) or Biologics License Application (BLA)
No peptide being reclassified from Category 2 to Category 1 has gone through this process.
Compounding ≠ Over-the-Counter
Even Category 1 peptides require a valid prescription from a licensed medical provider. They are compounded for individual patients based on specific physician orders. They are not available for purchase over the counter.
Research Use vs. Clinical Use
Research-grade peptides sold for laboratory purposes operate under a different framework than compounded medications intended for human administration. Research suppliers like Neogenesis BioLabs provide peptides with full certificates of analysis and third-party testing for use in research settings.
Why Quality Sourcing Matters
Regardless of regulatory category, the quality and purity of peptide compounds remains paramount. The 2023 restrictions inadvertently pushed demand toward unregulated sources with real risks: contamination, incorrect dosing, mislabeling, and zero quality control.
At Neogenesis BioLabs, every product ships with a certificate of analysis from independent third-party testing. We maintain strict quality control standards because access to high-quality research compounds should be the standard, not the exception.
Sources
- U.S. Food & Drug Administration — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a
- U.S. Federal Register — Pharmacy Compounding Advisory Committee; Notice of Meeting, Document No. 2026-07361. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- U.S. Congress — Federal Food, Drug, and Cosmetic Act, Section 503A. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section353a&num=0&edition=prelim
Last updated: April 17, 2026